eShowcase: VISTA
Shorter Study Start-Up Times Targeted with Site Assessment Process Tool
Shorter Study Start-Up Times Targeted with Site Assessment Process Tool
Scientific Software Tools (Media, PA) has released the latest version of VISTA, its Web-based automated site technology assessment service. The new service incorporates additional features to assess for e-clinical studies.
VISTA allows qualitative surveys conducted by the investigative site-—including the technology survey—to be completed online, which eliminates paper-based surveys and manual entry into a database. Also, this Web-based process allows investigators a single point of contact for all required surveys.
VISTA presents the data obtained from the surveys and the technical assessment in XML format, which allows for easier data sharing into databases, as well as improved data sharing between different systems used by all parties involved, including clinical staff, investigators, sponsors, and others.
VISTA Plus includes additional data capture and reporting, and VISTA Services includes additional components to the basic service.
Scientific Software Tools, Inc., (610) 891-1640, www.vistasurveys.com
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
